QLi5 Therapeutics has completed a €6.26 million capital increase led by its Korean co-founder, Qurient, which has also increased its voting stake in the German biotech. The funding will be used to advance QLi5’s proteasome inhibitor(PI)-based antibody-drug conjugate (ADC) payload platform, an approach the company is presenting as a next step beyond today’s dominant ADC payload classes.
For BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook extends far beyond 2030. Yet despite all the strategic preparation, one key question will be answered in the coming months: can the clinical data live up to the high expectations surrounding BioNTech’s cancer strategy?
The new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled an equally notable collaboration with US biotech pioneer Amgen, a partnership with a potential value of up to US$618 million.
On January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for a multi-year research and development collaboration to discover and develop oncology therapies using Insilico’s artificial intelligence (AI)-driven drug discovery platform and Servier’s cancer development expertise.
Swiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
Following a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at the Netherlands Cancer Institute (NKI) and Senior Investigator at Oncode Institute.
Cologne-based Disco Pharmaceuticals GmbH has closed its seed financing at €36m. The company will use the proceeds to advance its surfaceome-mapping platform, developing bispecific ADCs and T-Cell Engagers for hard-to-treat cancers.
Formycon AG and Zydus Lifesciences Limited today jointly announced a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), in the U.S. and Canada, the companies said in a statement.
Orano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production of alpha‑emitting radiopharmaceuticals.
California-based biotech Electra Therapeutics Inc has secured US$183m in Series C financing. The investment comes from a consortium of four European investors and Mubadala Capital. Contrary to some reports, more SIRPα modulators exist than the investors initially indicated.
BioNTech SE
Genentech Corp. / Roche
University of Geneva
MRM Health NV
adobe stock photos - deemerwha
Formycon AG
Orano Med SA
Pleiotrope - https://commons.wikimedia.org/w/index.php?curid=15999847